How Major Pharma Is Faring After the Brexit
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity…
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity…
The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials.…
Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations down into…
This week's top value calls from the analysts at Jefferies focus on blue chip companies that are, for the most part, very liquid and offer a degree of safety for investors.
Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive and allow for accelerating growth in the years to come.
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical stocks short interest decreased.
May 6, 2016: Here are four stocks trading with heavy volume among 83 equities making new 52-week lows in Friday’s session. NYSE advancers led decliners by nearly 2 to 1 while Nasdaq…
24/7 Wall St. is revisiting a strategy that was first published in late 2010, and then again refreshed in 2015. This is the 10 stocks to own for the decade!
Credit Suisse's new Neutral rating on Teva Pharmaceutical Industries actually comes with significant upside.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Anadarko Petroleum, Dollar General, Encana, FedEx, Teva Pharmaceutical and UBS.
The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical companies generate an estimated $300…